(S) Etifoxine Development Fund, LLC
SEDF funding the FDA approval process for a uniquely low risk, non-opiate, non-addictive, non-sedating, pain drug without GI side effects.
- Stage Product In Development
- Industry Biotechnology
- Location Metairie, LA, USA
- Currency USD
- Founded May 2012
- Employees 0
- Website ng-dg.com
Company Summary
SEDF was formed by a group of pharmaceutical industry veterans to develop (S)Etifoxine, an active component of an existing, clinically proven safe and effective drug as a novel, first-in-class pain treatment. Our management team and Strategic Advisory Board have extensive experience developing drugs with numerous large and medium sized pharmaceutical companies. (S)Etifoxine should make a significant difference in the way we treat pain.
Team
-
Brent A. KovachChief Executive Officer
-
Steven K. Duddy, Ph.D.Chief Scientific Officer
-
Layne E. Los, Ph.D.Chief Operating Officer
Advisors
-
Charles BerryLawyerUnconfirmedCraig SilvaAccountantUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.